



IDS

Infectious Diseases Society of America



hiv medicine association

IDS EXECUTIVE COMMITTEE

PRESIDENT

Stephen B. Calderwood, MD, FIDSA
Massachusetts General Hospital
Boston, MA

PRESIDENT-ELECT

Johan S. Bakken, MD, PhD, FIDSA
St. Luke's ID Associates
Duluth, MN

VICE-PRESIDENT

William G. Powderly, MD, FIDSA
Washington University School of Medicine
St. Louis, MO

SECRETARY

Penelope H. Dennehy, MD, FIDSA
Hasbro Children's Hospital/Brown University
Providence, RI

TREASURER

Cynthia L. Sears, MD, FIDSA
Johns Hopkins University School of Medicine
Baltimore, MD

IMMEDIATE PAST PRESIDENT

Barbara E. Murray, MD, FIDSA
University of Texas Health Science Center
Houston, TX

CHIEF EXECUTIVE OFFICER

Mark Leasure

HIVMA EXECUTIVE COMMITTEE

CHAIR

Adaora Adimora, MD, MPH, FIDSA
University of NC School of Medicine
Chapel Hill, NC

CHAIR-ELECT

Carlos del Rio, MD, FIDSA
Emory University
Atlanta, GA

VICE CHAIR

Wendy Armstrong, MD, FIDSA
Emory University
Decatur, GA

IMMEDIATE PAST CHAIR

Joel Gallant, MD, MPH, FIDSA
Southwest CARE Center
Sante Fe, NM

IDS REPRESENTATIVE

Judith Aberg, MD, FIDSA
Icahn School of Medicine at Mount Sinai
New York, NY

EXECUTIVE DIRECTOR

Andrea Weddle, MSW

IDS & HIVMA

1300 Wilson Blvd, Suite 300
Arlington VA, 22209
703-299-0200
www.idsociety.org
www.hivma.org

September 8, 2015

Tom Evegan
Turing Pharmaceuticals
Head of Managed Markets
1177 Avenue of the Americas, 39th Floor
New York, NY 10036
tom@turingpharma.com

Kevin Bernier
Turing Pharmaceuticals
National Director Alliance Development & Public Affairs
1177 Avenue of the Americas, 39th Floor
New York, NY 10036
kbernier@turingpharma.com

Dear Mr. Evegan and Mr. Bernier:

We are writing on behalf of the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) to urge Turing Pharmaceuticals to immediately revise the pricing strategy for the recently acquired drug pyrimethamine and to address distribution issues that are disrupting access to this generic medication used in the prevention and treatment of opportunistic infections.

IDSA represents more than 10,000 infectious diseases physicians and scientists devoted to patient care, prevention, public health, education and research. Our members care for patients of all ages with serious infections. Within IDSA, HIVMA represents more than 5,000 clinicians and researchers on the front lines of the HIV/AIDS epidemic.

In mid-August, after Turing purchased pyrimethamine, the price of the medication increased by 5000 percent¹ in hospital pharmacies around the country with no justification for an increase of this magnitude for a medication approved by the U.S. Food and Drug Administration in 1953.¹ In addition, hospitals, including those with 340B pharmacies, also reported being unable to obtain the medication.

Pyrimethamine is particularly important for the treatment of toxoplasmosis, a parasitic infection that has severe consequences if not effectively treated in pregnant women, patients with HIV infection, cancers and other conditions that compromise the immune system.

¹ The price per tablet is reported to have increased from \$13.50 per tablet to \$750 per tablet.

September 8, 2015

2

The Centers for Disease Control and Prevention has identified toxoplasmosis as one of five neglected parasitic diseases targeted for public health action because of the number of people infected, the severity of the illness and the ability for the condition to be treated.ⁱⁱ

Pyrimethamine is currently part of the recommended first line treatment regimen for toxoplasmosis in HIV-infected patients and is a critical component of most of the alternative regimens, particularly for those with allergies to sulfa agents.ⁱⁱⁱ Under the current pricing structure, it is estimated that the annual cost of treatment for toxoplasmosis, for the pyrimethamine component alone, will be \$336,000 for patients who weigh less than 60 kilograms and \$634,500 for patients who weigh more than 60 kilograms. This cost is unjustifiable for the medically vulnerable patient population in need of this medication and unsustainable for the health care system.

Please help us improve public health by immediately implementing a rational and fair pricing strategy for pyrimethamine that keeps treatment for a potentially fatal condition accessible to our patients. We may be contacted through the HIVMA executive director Andrea Weddle by email at aweddle@hivma.org or phone at (703) 299-0915 to discuss this issue.

Sincerely,



Stephen B. Calderwood, MD, FIDSA
President, IDSA



Adaora Adimora, MD, MPH, FIDSA
Chair, HIVMA

ⁱ AIDSinfo database. Pyrimethamine. Online at:

<https://aidsinfo.nih.gov/drugs/445/pyrimethamine/0/professional> (accessed 9/4/2015).

ⁱⁱ Centers for Disease Control and Prevention. Neglected Parasitic Infections (NPIs) in the United States. Online at: <http://www.cdc.gov/parasites/npi/> (accessed 9/4/2015).

ⁱⁱⁱ U.S. Department of Health and Human Services. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Online at: <https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/322/toxo> (accessed 9/4/2015).